Jennifer A Wargo

List of Publications by Year
in descending order

201 papers	46,980 citations	6254 80 h-index	2385 198 g-index
216 all docs	216 docs citations	216 times ranked	46602 citing authors

#	Article	IF	Citations
1	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	1.5	21
2	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunology Research, 2022, 10, 303-313.	3.4	1
3	Evolution of FMT â€" From early clinical to standardized treatments. Biologicals, 2022, , .	1.4	3
4	Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunology Research, 2022, 10, 259-271.	3.4	10
5	Mechanisms of immune activation and regulation: lessons from melanoma. Nature Reviews Cancer, 2022, 22, 195-207.	28.4	101
6	Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210830.	3.2	13
7	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Reports Medicine, 2022, 3, 100500.	6.5	13
8	Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. Practical Radiation Oncology, 2022, 12, 437-445.	2.1	5
9	Immunotherapy response-associated Akkermansia: canary in a coal mine?. Trends in Immunology, 2022, , .	6.8	3
10	Utilization and evolving prescribing practice of opioid and nonâ€opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. Journal of Surgical Oncology, 2022, 125, 719-729.	1.7	1
11	Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. Journal of Investigative Dermatology, 2022, 142, 2046-2049.e3.	0.7	8
12	Glioma and the gutâ€"brain axis: opportunities and future perspectives. Neuro-Oncology Advances, 2022, 4, vdac054.	0.7	10
13	Targeting the gut and tumor microbiota in cancer. Nature Medicine, 2022, 28, 690-703.	30.7	159
14	Gut microbes as biomarkers of ICI response â€" sharpening the focus. Nature Reviews Clinical Oncology, 2022, 19, 495-496.	27.6	5
15	Neoadjuvant therapy for melanoma: new and evolving concepts.. Clinical Advances in Hematology and Oncology, 2022, 20, 47-55.	0.3	0
16	Trust your gut when it comes to driving CARs. Med, 2022, 3, 281-283.	4.4	1
17	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell, 2022, 40, 509-523.e6.	16.8	115
18	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature, 2022, 606, 797-803.	27.8	54

#	Article	IF	Citations
19	Multi-modal molecular programs regulate melanoma cell state. Nature Communications, 2022, 13, .	12.8	9
20	Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia, 2022, 31, 100813.	5.3	14
21	Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science, 2021, 371, 602-609.	12.6	784
22	Considerations for designing preclinical cancer immune nanomedicine studies. Nature Nanotechnology, 2021, 16, 6-15.	31.5	77
23	Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature, 2021, 590, 332-337.	27.8	81
24	Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. Journal of Cutaneous Pathology, 2021, 48, 674-679.	1.3	4
25	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nature Communications, 2021, 12, 346.	12.8	107
26	Fecal microbiota transplantation as a mean of overcoming immunotherapy-resistant cancers â€" hype or hope?. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110458.	3.2	8
27	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	30.7	357
28	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine, 2021, 27, 301-309.	30.7	218
29	Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Communications Biology, 2021, 4, 237.	4.4	62
30	The microbiome and human cancer. Science, 2021, 371, .	12.6	506
31	Identification of bacteria-derived HLA-bound peptides in melanoma. Nature, 2021, 592, 138-143.	27.8	187
32	A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS ONE, 2021, 16, e0247905.	2.5	20
33	Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect. Cancer Immunology Research, 2021, 9, 365-370.	3.4	28
34	Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Annals of Surgical Oncology, 2021, 28, 3480-3489.	1.5	7
35	Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2021, 27, 4557-4565.	7.0	61
36	Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Nature Communications, 2021, 12, 4031.	12.8	21

#	Article	IF	Citations
37	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	30.7	216
38	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 5365-5375.	7.0	29
39	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nature Communications, 2021, 12, 5045.	12.8	42
40	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nature Communications, 2021, 12, 5606.	12.8	76
41	Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell, 2021, 184, 5338-5356.e21.	28.9	229
42	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell, 2021, 184, 5309-5337.	28.9	588
43	Identification of MicroRNAâ€"mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers, 2021, 13, 5301.	3.7	7
44	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i> -mutated melanoma. OncoImmunology, 2021, 10, 1992880.	4.6	7
45	Coenzyme A fuels TÂcell anti-tumor immunity. Cell Metabolism, 2021, 33, 2415-2427.e6.	16.2	31
46	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science, 2021, 374, 1632-1640.	12.6	369
47	More fuel for the fire: Gut microbes and toxicity to immune agonist antibodies in cancer. Cell Reports Medicine, 2021, 2, 100482.	6.5	1
48	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Modern Pathology, 2020, 33, 496-513.	5.5	19
49	Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 349-357.	0.8	27
50	Functional annotation of melanoma risk loci identifies novel susceptibility genes. Carcinogenesis, 2020, 41, 452-457.	2.8	15
51	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Annals of Oncology, 2020, 31, 1569-1579.	1.2	18
52	Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?. Nature Reviews Immunology, 2020, 20, 522-528.	22.7	54
53	Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. Journal of Experimental Medicine, 2020, 217, .	8.5	142
54	Gut Microbesâ€™ Impact on Oncogenic Drivers: Location Matters. Molecular Cell, 2020, 79, 878-880.	9.7	2

#	Article	IF	Citations
55	Modulating gut microbes. Science, 2020, 369, 1302-1303.	12.6	60
56	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunology Research, 2020, 8, 1365-1380.	3.4	37
57	The human tumor microbiome is composed of tumor typeâ€"specific intracellular bacteria. Science, 2020, 368, 973-980.	12.6	1,077
58	Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers. Current Oncology Reports, 2020, 22, 74.	4.0	34
59	Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review. Seminars in Hematology, 2020, 57, 13-18.	3.4	11
60	Gut Microbiome Modulates Response to Cancer Immunotherapy. Digestive Diseases and Sciences, 2020, 65, 885-896.	2.3	38
61	The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends in Cancer, 2020, 6, 192-204.	7.4	162
62	Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. Nature Communications, 2020, 11, 853.	12.8	23
63	B cells are associated with survival and immunotherapy response in sarcoma. Nature, 2020, 577, 556-560.	27.8	1,158
64	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature, 2020, 577, 561-565.	27.8	1,209
65	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	27.8	1,421
66	Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. Annals of Surgical Oncology, 2020, 27, 1533-1545.	1.5	6
67	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	1.6	23
68	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2020, 140, 2146-2156.e4.	0.7	14
69	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nature Communications, 2020, 11, 1839.	12.8	15
70	Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clinical Cancer Research, 2020, 26, 1258-1266.	7.0	115
71	The Microbiome in Immuno-oncology. Advances in Experimental Medicine and Biology, 2020, 1244, 325-334.	1.6	7
72	AI finds microbial signatures in tumours and blood across cancer types. Nature, 2020, 579, 502-503.	27.8	9

#	Article	IF	Citations
73	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	12.8	140
74	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clinical Cancer Research, 2020, 26, 1886-1895.	7.0	42
75	Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. Blood, 2020, 136, 34-35.	1.4	1
76	Spitzoid melanoma with histopathological features of <i> <scp>ALK</scp> </i> gene rearrangement exhibiting <i> <scp>ALK</scp> </i> copy number gain: a novel mechanism of <scp>ALK</scp> activation in spitzoid neoplasia. British Journal of Dermatology, 2019, 180, 404-408.	1.5	5
77	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clinical Cancer Research, 2019, 25, 1233-1238.	7.0	260
78	Microbiome and Melanoma. , 2019, , 287-302.		0
79	Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell, 2019, 178, 795-806.e12.	28.9	830
80	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nature Immunology, 2019, 20, 1231-1243.	14.5	217
81	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155
82	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. Surgical Oncology Clinics of North America, 2019, 28, 369-386.	1.5	19
83	Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22246-22251.	7.1	142
84	Combination antiâ€"CTLA-4 plus antiâ€"PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22699-22709.	7.1	226
85	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Research, 2019, 29, 846-861.	12.0	160
86	Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncology, The, 2019, 20, e77-e91.	10.7	249
87	Role of Immune Response, Inflammation, and Tumor Immune Responseâ€"Related Cytokines/Chemokines in Melanoma Progression. Journal of Investigative Dermatology, 2019, 139, 2352-2358.e3.	0.7	23
88	The cancer microbiome. Nature Reviews Cancer, 2019, 19, 371-376.	28.4	153
89	Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. Cancers, 2019, 11, 754.	3.7	21
90	Neoadjuvant therapy for melanoma: is it ready for prime time?. Lancet Oncology, The, 2019, 20, 892-894.	10.7	7

#	Article	IF	Citations
91	Antiâ€“CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancersâ€"Response. Clinical Cancer Research, 2019, 25, 3469-3470.	7.0	151
92	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research, 2019, 7, 1025-1035.	3.4	70
93	Microbiome and Melanoma. , 2019, , 1-16.		0
94	Gene expression profiling of lichenoid dermatitis immuneâ€related adverse event from immune checkpoint inhibitors reveals increased CD14⁺ and CD16⁺ monocytes driving an innate immune response. Journal of Cutaneous Pathology, 2019, 46, 627-636.	1.3	27
95	The microbiome, cancer, and cancer therapy. Nature Medicine, 2019, 25, 377-388.	30.7	712
96	B7-H3 Expression in Merkel Cell Carcinomaâ€“Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clinical Cancer Research, 2019, 25, 3455-3467.	7.0	24
97	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discovery, 2019, 9, 628-645.	9.4	231
98	The Tumor Microbiome in Pancreatic Cancer: Bacteria and Beyond. Cancer Cell, 2019, 36, 577-579.	16.8	72
99	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1692-1697.	7.1	237
100	Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discovery, 2019, 9, 64-81.	9.4	260
101	A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF^{high}/AXL^{low} melanoma. Pigment Cell and Melanoma Research, 2019, 32, 280-291.	3.3	31
102	Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors. Cancer Research, 2019, 79, 2838-2838.	0.9	50
103	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clinical Cancer Research, 2018, 24, 3366-3376.	7.0	73
104	A Preexisting Rare <i>PIK3CA</i>E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in <i>NRAS</i> Melanoma and Is Dependent on S6K1 Signaling. Cancer Discovery, 2018, 8, 556-567.	9.4	55
105	The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. Annals of Surgical Oncology, 2018, 25, 1814-1827.	1.5	45
106	Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. Journal of Cutaneous Pathology, 2018, 45, 545-549.	1.3	5
107	The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell, 2018, 33, 570-580.	16.8	911
108	The gut microbiota influences anticancer immunosurveillance and general health. Nature Reviews Clinical Oncology, 2018, 15, 382-396.	27.6	389

#	Article	IF	Citations
109	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. OncoImmunology, 2018, 7, e1423172.	4.6	25
110	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2018, 19, 181-193.	10.7	233
111	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncology, The, 2018, 19, 310-322.	10.7	486
112	Predictors of Response to Immune Checkpoint Blockade. , 2018, , 525-544.		0
113	Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. , 2018, 6, 14.		118
114	Gut microbiome modulates response to antiâ€"PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103.	12.6	3,126
115	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. OncoImmunology, 2018, 7, e1385689.	4.6	46
116	Combination Immunotherapy Development in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 197-207.	3.8	39
117	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine, 2018, 24, 1804-1808.	30.7	521
118	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654.	30.7	592
119	Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer, 2018, 18, 913.	2.6	69
120	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell, 2018, 175, 998-1013.e20.	28.9	1,260
121	The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends in Immunology, 2018, 39, 900-920.	6.8	56
122	Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discovery, 2018, 8, 1366-1375.	9.4	80
123	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 2018, 29, 1861-1868.	1.2	135
124	High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. OncoImmunology, 2018, 7, e1475874.	4.6	20
125	Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. Frontiers in Immunology, 2018, 9, 946.	4.8	19
126	Linking Associations of Rare Low-Abundance Species to Their Environments by Association Networks. Frontiers in Microbiology, 2018, 9, 297.	3.5	19

#	Article	IF	Citations
127	Immune Checkpoint Blockade across the Cancer Care Continuum. Immunity, 2018, 48, 1077-1080.	14.3	33
128	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, .	12.4	689
129	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 2017, 168, 707-723.	28.9	3,483
130	Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. Journal of Investigative Dermatology, 2017, 137, 1792-1795.	0.7	40
131	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. Journal of Experimental Medicine, 2017, 214, 1691-1710.	8.5	71
132	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discovery, 2017, 7, 832-851.	9.4	49
133	Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?. Clinical Cancer Research, 2017, 23, 327-329.	7.0	1
134	Clinicopathological features and clinical outcomes associated with <i>TP53</i> and <i>BRAF</i>^{<i>N</i>}^{<i>onâ€«</i>}^{<i>V</i>}^{<i>600</i>} mutations in cutaneous melanoma patients. Cancer, 2017, 123, 1372-1381.	4.1	36
135	Hallmarks of response to immune checkpoint blockade. British Journal of Cancer, 2017, 117, 1-7.	6.4	194
136	Interaction of molecular alterations with immune response in melanoma. Cancer, 2017, 123, 2130-2142.	4.1	24
137	Immunotherapy resistance: the answers lie ahead â€“ not in front â€“ of us. , 2017, 5, 10.		13
138	VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 2017, 23, 551-555.	30.7	467
139	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	3.8	120
140	Cancer Evolution during Immunotherapy. Cell, 2017, 171, 740-742.	28.9	28
141	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications, 2017, 8, 607.	12.8	109
142	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science, 2017, 357, 1156-1160.	12.6	1,059
143	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Molecular Medicine, 2017, 9, 1011-1029.	6.9	63
144	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 2017, 7, 1088-1097.	9.4	160

#	Article	IF	Citations
145	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell, 2017, 170, 1120-1133.e17.	28.9	960
146	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. OncoImmunology, 2017, 6, e1361097.	4.6	50
147	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports, 2017, 21, 1936-1952.	6.4	72
148	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. OncoImmunology, 2017, 6, e1321187.	4.6	45
149	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. Journal of Cutaneous Pathology, 2017, 44, 158-176.	1.3	186
150	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. Journal of Translational Medicine, 2017, 15, 223.	4.4	25
151	Uveal melanoma: From diagnosis to treatment and the science in between. Cancer, 2016, 122, 2299-2312.	4.1	272
152	Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2016, 23, 609-617.	1.5	24
153	Monitoring immune responses in the tumor microenvironment. Current Opinion in Immunology, 2016, 41, 23-31.	5.5	96
154	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Current Oncology Reports, 2016, 18, 42.	4.0	54
155	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature, 2016, 532, 250-254.	27.8	290
156	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitorâ€"Refractory Metastatic Melanoma. JAMA Oncology, 2016, 2, 1056.	7.1	41
157	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. Clinical Cancer Research, 2016, 22, 5553-5563.	7.0	96
158	Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Molecular Cancer Therapeutics, 2016, 15, 2442-2454.	4.1	47
159	The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416.	3.3	77
160	Loss of IFN-Î³ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell, 2016, 167, 397-404.e9.	28.9	1,009
161	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine, 2016, 14, 168.	5.5	106
162	The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer, 2016, 122, 2186-2196.	4.1	121

#	Article	IF	Citations
163	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	9.4	785
164	Loss of PTEN Promotes Resistance to T Cellâ€“Mediated Immunotherapy. Cancer Discovery, 2016, 6, 202-216.	9.4	1,158
165	Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. Journal of Clinical Oncology, 2016, 34, 1741-1747.	1.6	64
166	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell, 2016, 29, 270-284.	16.8	198
167	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology, 2016, 5, e1136044.	4.6	55
168	Working with Human Tissues for Translational Cancer Research. Journal of Visualized Experiments, 2015, , .	0.3	2
169	Use of clinical nextâ€generation sequencing to identify melanomas harboring <i><scp>SMARCB1</scp></i> mutations. Journal of Cutaneous Pathology, 2015, 42, 308-317.	1.3	11
170	Update on use of aldesleukin for treatment of high-risk metastatic melanoma. ImmunoTargets and Therapy, 2015, 4, 79.	5.8	21
171	Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS ONE, 2015, 10, e0139851.	2.5	47
172	Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. Clinical Cancer Research, 2015, 21, 3102-3104.	7.0	27
173	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Reports, 2015, 11, 1458-1473.	6.4	55
174	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nature Genetics, 2015, 47, 250-256.	21.4	434
175	EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. Cancer Discovery, 2015, 5, 274-287.	9.4	107
176	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Seminars in Oncology, 2015, 42, 601-616.	2.2	139
177	MITF Modulates Therapeutic Resistance through EGFR Signaling. Journal of Investigative Dermatology, 2015, 135, 1863-1872.	0.7	76
178	Cancer Genomics in Clinical Context. Trends in Cancer, 2015, 1, 36-43.	7.4	6
179	BRAF Inhibition Generates a Hostâ€“Tumor Niche that Mediates Therapeutic Escape. Journal of Investigative Dermatology, 2015, 135, 3115-3124.	0.7	80
180	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Human Pathology, 2015, 46, 1101-1110.	2.0	43

#	Article	IF	Citations
181	Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS ONE, 2015, 10, e0140310.	2.5	39
182	Raising the bar: optimizing combinations of targeted therapy and immunotherapy. Annals of Translational Medicine, 2015, 3, 272.	1.7	0
183	RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma. Journal of Pigmentary Disorders, 2014, 01, .	0.2	0
184	Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation. Journal of Immunology, 2014, 193, 4722-4731.	0.8	136
185	Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. OncoImmunology, 2014, 3, e954956.	4.6	19
186	Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer. Cancer Discovery, 2014, 4, 1377-1386.	9.4	76
187	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1Î± and Oxidative Phosphorylation in Melanoma. Cancer Research, 2014, 74, 7037-7047.	0.9	161
188	The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFÎ±. Cancer Discovery, 2014, 4, 1214-1229.	9.4	174
189	Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. Cancer Immunology Research, 2014, 2, 643-654.	3.4	226
190	A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. Cancer Discovery, 2014, 4, 816-827.	9.4	448
191	Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biology and Medicine, 2014, 11, 237-46.	3.0	64
192	BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clinical Cancer Research, 2013, 19, 1225-1231.	7.0	832
193	BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. Clinical Cancer Research, 2013, 19, 393-403.	7.0	336
194	BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. OncoImmunology, 2013, 2, e26615.	4.6	97
195	Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. Clinical Cancer Research, 2012, 18, 5329-5340.	7.0	266
196	A Landscape of Driver Mutations in Melanoma. Cell, 2012, 150, 251-263.	28.9	2,247
197	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 2012, 487, 500-504.	27.8	1,561
198	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 2011, 480, 387-390.	27.8	1,298

#	Article	IF	Citations
199	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 2010, 468, 968-972.	27.8	1,325
200	Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function. Cancer Research, 2010, 70, 5213-5219.	0.9	659
201	The Gut and Cervical Microbiome Promote Immune Activation and Response to Chemoradiation in Cervical Cancer. SSRN Electronic Journal, 0, , .	0.4	3